SYNPO antibodies target synaptopodin, a cytoskeleton-associated protein encoded by the *SYNPO* gene. Synaptopodin is predominantly expressed in renal podocytes and neuronal dendritic spines, playing critical roles in maintaining cell structure and dynamic processes. In podocytes, it interacts with actin filaments and α-actinin-4. regulating foot process architecture and glomerular filtration. Its neuronal counterpart influences synaptic plasticity by modulating actin dynamics in dendritic spines.
SYNPO's association with kidney and neurological disorders has driven research interest. In nephrology, reduced synaptopodin levels correlate with podocyte injury in diseases like focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy, making it a biomarker for glomerular damage. In neuroscience, synaptopodin loss is linked to cognitive deficits in Alzheimer’s disease and schizophrenia.
SYNPO antibodies are vital tools for detecting synaptopodin in immunoassays (e.g., Western blot, immunohistochemistry). They help study protein expression patterns, subcellular localization, and pathophysiological changes in disease models. Commercially available antibodies vary in specificity (e.g., targeting different isoforms: SYNPO-short in neurons, SYNPO-long in podocytes). Validation remains essential due to cross-reactivity risks. Research using SYNPO antibodies continues to unravel its roles in cytoskeletal regulation and disease mechanisms, aiding therapeutic development.